The name change touches on the company’s AI and machine learning proficiencies, while including the expansion of the company’s mission to serve additional regulated industries including animal health, cosmetics, medical devices, specialty chemicals, nutraceuticals, and food and beverage.
Bigfinite, an artificial intelligence (AI) and advanced analytics platform company, announced on Oct. 5, 2020 that it is changing its name to Aizon to highlight its capabilities and expansion of its mission plan.
According to a company press release, the name change touches on the company’s AI and machine learning proficiencies while including the expansion of the company’s mission to serve additional regulated industries, including animal health, cosmetics, medical devices, specialty chemicals, nutraceuticals, and food and beverage.
“This is a symbol of change, not a change of symbol. Markets are increasingly in need of advanced artificial intelligence, flexible [Internet of things] data acquisition, compliant data lakes, deep learning, and other industrial-grade technologies,” said John Vitalie, CEO of Aizon, in the press release. “Aizon is well positioned to help those manufacturing sectors meet stringent regulatory requirements and extract deeper understanding of complex processes, which ultimately leads to new sources of value. This is especially critical as the demand to scale production with even more efficiency increases—as we see with pharma and other regulated industries.”
Source: Aizon
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.